CirCode
Latest round
- Series A
Last raised
- Aug 2023
Total raised
- $10M
Investors
- 4
About CirCode
Established in 2021 and based in Shanghai, China, CirCode is a biomedical developer that focus on circular RNA drugs. The founder Prof. Zefeng Wang served as the professor of the institute of nutrition and health of the Chinese Academy of Sciences and the director of the laboratory of computational biology of the Chinese Academy of Sciences. The Company first discovered in 2014 that cyclic RNA can be translated to generate proteins with different functions in human cells, pioneering the use of cyclic RNA as a novel mRNA therapy. The Company utilizes its proprietary cyclic RNA technology platform to develop therapeutic drugs and vaccines. The company has an independently developed patent, which is based on the activity of type II intronic self-scrambling nuclease that can ring any RNA in vitro, and a sequence design platform that can design and optimize the sequence of translation initiation elements and coding regions to achieve efficient translation of ring RNA. The company business is self-develop circular RNA drugs.
Who invested in CirCode
4 investors across 2 rounds
See all investors in CirCode
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about CirCode
Who invested in CirCode?
CirCode has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CirCode raised?
CirCode has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did CirCode last raise money?
CirCode's most recent round on record is a Series A, in Aug 2023.
What does CirCode do?
Established in 2021 and based in Shanghai, China, CirCode is a biomedical developer that focus on circular RNA drugs.
Where is CirCode headquartered?
CirCode is headquartered in Shanghai, China.
Which VCs invest in companies like CirCode?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at CirCode's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like CirCode? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.